GENZYME CORPORATION for GENZYME CORPORATION

Taxation/Internal Revenue Code TAX

Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Excise Tax for Drugs and Biologics Extension of R& D Tax Credit Orphan Drug Tax CreditImplementation of American Taxpayer Relief Act of 2012 Tax Reform

Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.

Contacted: Agency for Healthcare Research & Quality (AHRQ); SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS)

Health Issues HCR

Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues AHRQ Studies of Orphan DrugsDrug Supply Chain Security: H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013 and S. 959, Pharmaceutical Compounding Quality and Accountability Act H.R. 1281, Newborn Screening Saves Lives Reauthorization Act of 2013

Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.

Contacted: SENATE; Health & Human Services, Dept of (HHS); Agency for Healthcare Research & Quality (AHRQ); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Bills named: H.R. 1281 (113th), H.R. 1919 (113th), S. 959 (113th)

Medicare/Medicaid MMM

ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 800, to exclude prompt pay discounts from the average sales price for drugs and biologics under Medicare Part B H.R. 1516, Cancer Patient Protection Act of 2013

Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.

Contacted: Agency for Healthcare Research & Quality (AHRQ); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 117 (113th), H.R. 413 (113th), H.R. 1516 (113th), H.R. 800 (113th), S. 77 (113th)

Budget/Appropriations BUD

FY 2013 Budget FY 2014 Budget FY 2013 Appropriations - Labor-HHS, Agriculture and FDA

Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.

Contacted: SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Agency for Healthcare Research & Quality (AHRQ); Centers For Medicare and Medicaid Services (CMS)

Pharmacy PHA

Food and Drug Administration Safety and Innovation Act Implementation Biosimilars Exclusivity Period in Administration's Budget Proposal Prescription Drug Compounding: S. 959, Pharmaceutical Compounding Quality and Accountability Act; H.R. 2186, VALID Compounding Act; The Compounding Clarity ActDrug Supply Chain Security: S. 959, Pharmaceutical Compounding Quality and Accountability Act, and H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013

Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.

Contacted: HOUSE OF REPRESENTATIVES; Agency for Healthcare Research & Quality (AHRQ); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: S. 959 (113th), H.R. 2186 (113th), H.R. 1919 (113th)